Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours

European Journal of Cancer

Volumn 45, Issue 12, 2009, Pages 2116-2122

  Sessa, C ^a,b   Cresta, S ^b   Noberasco, C ^c   Capri, G ^b   Gallerani, E ^a,d   Braud, F De ^c   Zucchetti, M ^e   D'Incalci, M ^e   Locatelli, A ^b   Marsoni, S ^f   Corradino, I ^f   Minoia, C ^g   Zintl, P ^h   Gianni, L ^b  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f Southern Europe New Drug Organization SENDO   (Italy)

^g IRCCS   (Italy)

^h PHARMAMAR S A   (Spain)

Author keywords

Cisplatin; Combination; Ovarian cancer; Pharmacokinetics; Phase I; Trabectedin

Indexed keywords

CISPLATIN; DEXAMETHASONE; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST; TRABECTEDIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEIOMYOSARCOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; UTERUS LEIOMYOSARCOMA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DIOXOLES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OVARIAN NEOPLASMS; TETRAHYDROISOQUINOLINES;

EID: 67651089735     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.002     Document Type: Article

References (14)

1. Sessa C., De Braud F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23 9 (2005) 1867-1874
2. Minuzzo M., Marchini S., Broggini M., et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97 12 (2000) 6780-6784
3. Minuzzo M., Ceribelli M., Pitarque-Martì M., et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 68 5 (2005) 1496-1503
4. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92 4 (2001) 583-588
5. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44 4 (2008) 609-618
6. Soares D.G., Escargueil A.E., Poindessous V., et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 104 32 (2007) 13062-13067
7. Damia G., and D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43 12 (2007) 1791-1801
8. D'Incalci M., Colombo T., Ubezio P., et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39 13 (2003) 1920-1926
9. Sessa C., Perotti A., Noberasco C., et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer (2009) 10.1016/j.ejca.04.002
10. Clamp A., and Jayson G.C. Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer 86 1 (2002) 19-25
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
12. Rosing H., Hillebrand M.J.X., Jimeno J., et al. Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 33 (1998) 1134-1140
13. Twelves C., Hoekman K., Bowman A., et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 39 (2003) 1842-1851
14. Messersmith W.A., Jimeno A., Ettinger D., et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 63 1 (2008) 181-188